Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00670189 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
A Phase 1 study of Basal Cell Carcinoma (BCC) and Hedgehog Pathway, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 3
- Study locations
NCT00670189: Completed Phase 1 study of Basal Cell Carcinoma (BCC) and Hedgehog Pathway, sponsored by Bristol-Myers Squibb.
NCT00670189 is a Phase 1 study of Basal Cell Carcinoma (BCC) and Hedgehog Pathway that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 53 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00670189, a Phase 1 study of Basal Cell Carcinoma (BCC) and Hedgehog Pathway, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule
Primary Outcome
Use NCI CTCAE to monitor safety assessments including physical findings, laboratory tests, and radiographic assessments to establish the maximum tolerated dose and recommended Phase 2 dose range and schedule of BMS-833923
Conditions Studied
Interventions
- DRUG BMS-833923 (XL139)
Study Locations (3)
Minnesota
- Mayo Clinic Rochester - Rochester
Texas
- Southwest Texas Addiction Research And Tech (Start) Center - San Antonio
Ontario
- Local Institution - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2008-07 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
What the finished NCT00670189 record still lists
NCT00670189 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower).
The record links to 4 conditions, with Basal Cell Carcinoma (BCC) appearing as the primary indexed condition, and to 1 intervention - of which BMS-833923 (XL139) is the first listed.
NCT00670189 reports a single indexed study location in Minnesota, Texas, Ontario.
Frequently Asked Questions
What is clinical trial NCT00670189 about?
NCT00670189 is a clinical study titled "A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer". The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule
What is the current status of trial NCT00670189?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2008-07. Estimated completion is 2014-05.
What conditions does trial NCT00670189 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma (BCC), Hedgehog Pathway, Smoothened, Basal Cell Nevoid Syndrome (BCNS).
What interventions are being tested in trial NCT00670189?
The interventions under investigation include: BMS-833923 (XL139) (DRUG).
Who is sponsoring clinical trial NCT00670189?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00670189 being conducted?
This trial has 3 study locations across Minnesota, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Basal Cell Carcinoma (BCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00670189's enrollment target sits among peer trials
53 948th of 2000 higher than 1,045 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia